Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?. (29th July 2018)

• Record Type: Journal Article
• Authors: Vozmediano-Chicharro, Raúl; Madurga, Blanca; Blasco, Pedro
• Other Names: Rutman Matthew Academic Editor.
• Is Part Of: Advances in urology. Volume 2018(2018)
• Publication Date: 2018-07-29
• Subjects: Urology -- Periodicals; 616.6005
• DOI: 10.1155/2018/6782736
• Languages: English
• ISSNs: 1687-6369

Abstract

Abstract : Objectives . Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up. Methods . This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years. Results . Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p < 0.001 ); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p < 0.001 ); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p < 0.001 ). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth. Conclusions . Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.